Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 37.9% during mid-day trading on Friday . The stock traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares traded hands during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The company has a market capitalization of C$17.42 million, a P/E ratio of -10.00 and a beta of 0.20. The firm’s 50-day moving average is C$0.09 and its 200-day moving average is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- 3 REITs to Buy and Hold for the Long Term
- 3 EV Stocks Offering Unique Alternatives to Tesla
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Stocks Leveraging NVIDIA’s Strength for Profits
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Walgreens Stock Poised for a Rebound: Why Analysts Are Bullish
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
